[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Viswambharan JK, Kadambari D, Iyengar KR, Srinivasan K: Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy. Indian J Cancer; 2005 Jan-Mar;42(1):30-4
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy.
  • BACKGROUND: The response of locally advanced breast cancer (LABC) to neoadjuvant chemotherapy (NACT) offers these patients previously treated by mastectomy, the chance for breast conservation.
  • AIM: This study aims to assess the feasibility of lumpectomy in patients with LABC treated by NACT, with residual tumor < or =5 cm.
  • Simulation lumpectomy was performed on the mastectomy specimens to achieve 1 to 2 cm clearance from tumor and hence margin negativity.
  • Fourteen out of thirty (47%) had tumor involvement of margins.
  • Tumors with post-chemotherapy size> 4 cm were margin positive in 10/13 (77%).
  • Tumors with post-chemotherapy size>3 cm were margin positive in 13/24 (54%).
  • Tumors with post-chemotherapy size 3 cm were margin negative in 5/6 (83%).
  • Pre-chemotherapy tumor size and post-chemotherapy tumor size were significantly associated with margin positivity (P=0.003).
  • Tumors in the subareolar location had significantly higher incidence of residual tumor in the nipple areola complex. (P=0.04).
  • Margin positivity of lumpectomy on downstaged tumors can be reduced by removing the nipple areola complex in subareolar tumors and by limiting breast conservation to tumors with post-chemotherapy size < or =3 cm.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Mastectomy / methods. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805689.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Sato T, Muto I, Hasegawa M, Aono T, Okada T, Tamura T, Sakai T: A rare case of invasive ductal carcinoma with hyperprolactinemia. Breast Cancer; 2007;14(3):302-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here a rare form of invasive ductal carcinoma composed of a mass protruding from the tip of the nipple in a 43-year-old woman with hyperprolactinemia.
  • She presented with a mass on the left nipple that had been growing for 6 months.
  • Morphologically, the mass resembled adenoma of the nipple.
  • Histopathologically, the tumor of the nipple was invasive ductal carcinoma, which had extended intraductally from another invasive ductal carcinoma in the subareolar region, and had infiltrated the epidermis of the nipple (Paget's disease).
  • The patient was treated with bromocriptine mesilate, in addition to adjuvant chemotherapy for breast cancer, and the plasma prolactin level has since normalized.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Hyperprolactinemia / etiology. Nipples / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Mammography

  • Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.
  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690509.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


3. Sauter ER, Ehya H, Mammen A, Klein G: Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy. Br J Cancer; 2001 Dec 14;85(12):1952-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy.
  • We previously demonstrated that abnormal nipple aspirate fluid (NAF) cytology predicted residual breast cancer (RC) and tumour size after excisional biopsy (EB), although normal NAF cytology did not exclude RC.
  • LN metastases provide prognostic information allowing medical and radiation oncologists to determine the need for adjuvant therapy.
  • NAF cytology and pathologic parameters: tumour distance from biopsy margins, multifocal and multicentric disease, sub-type of ductal carcinoma in situ (DCIS) or invasive cancer (IC), grade of DCIS or IC, tumour and specimen size, tumour and biopsy cavity location, presence or absence of extensive DCIS, and biopsy scar distance from the nipple were evaluated bivariately and then by logistic regression (LR) for their association with RC and involved LN (> or = 1 (+) LN, useful to determine chemotherapy need, and > or = 4 (+) LN, useful to determine radiation need to the chest and axilla).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(7):1222-7 [10584885.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):829-34 [1168727.001]
  • [Cites] Am J Clin Pathol. 1975 Dec;64(6):728-38 [1202937.001]
  • [Cites] J Natl Cancer Inst. 1983 Dec;71(6):1115-21 [6581355.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] Semin Surg Oncol. 1992 May-Jun;8(3):122-8 [1496221.001]
  • [Cites] Arch Surg. 1993 Sep;128(9):1014-8; discussion 1018-20 [8396387.001]
  • [Cites] Ann Surg. 1993 Dec;218(6):729-34 [8257222.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):130-41 [1536131.001]
  • (PMID = 11747339.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 87391
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2364009
  •  go-up   go-down


Advertisement
4. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA: Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):351-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
  • PURPOSE: To identify the clinical and pathologic factors predictive of locoregional recurrence (LRR) after neoadjuvant chemotherapy, mastectomy, and radiotherapy.
  • METHODS AND MATERIALS: We retrospectively reviewed the hospital records of 542 patients treated on six consecutive institutional prospective trials using neoadjuvant chemotherapy and postmastectomy radiotherapy.
  • The clinical factors associated with LRR included combined clinical stage, clinical T stage, ipsilateral supraclavicular nodal disease, chemotherapy response, physical examination size after chemotherapy, and no tamoxifen use (p < or = 0.04 for all factors).
  • The pathologic predictors of LRR included the number of positive nodes, dissection of <10 nodes, multifocal/multicentric disease, lymphovascular space invasion, extracapsular extension, skin/nipple involvement, and estrogen receptor-negative disease (p <or = 0.05 for all factors).
  • Multivariate Cox regression analysis revealed that five factors independently predicted for LRR: skin/nipple involvement, supraclavicular nodal disease, no tamoxifen use, extracapsular extension, and estrogen receptor-negative disease (hazard ratio, 2.1-2.8; p < or = 0.02 for all factors).
  • CONCLUSION: Although the long-term rate of LRR after neoadjuvant chemotherapy, mastectomy, and radiotherapy is low, we identified a number of factors that correlated independently with greater rates of LRR.
  • Patients with three or more of these factors may benefit from research protocols investigating alternative treatment strategies.
  • [MeSH-major] Breast Neoplasms / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Nipples / pathology. Regression Analysis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890574.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / T32CA77050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J: [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Cancer Radiother; 2004 Jun;8(3):155-67
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
  • [Transliterated title] Cancer du sein localement évolué non inflammatoire traité par association de chimiothérapie et de radiothérapie à dose préopératoire: réactualisation des résultats d'une série de 120 patientes.
  • PURPOSE: To evaluate our updated data concerning survival and locoregional control in a study of locally advanced non inflammatory breast cancer after primary chemotherapy followed by external preoperative irradiation.
  • PATIENTS AND METHODS: Between 1982 and 1998, 120 patients (75 stage IIIA, 41 stage IIIB, and 4 stage IIIC according to AJCC staging system 2002) were consecutively treated by four courses of induction chemotherapy with anthracycline-containing combinations followed by preoperative irradiation (45 Gy to the breast and nodal areas) and a fifth course of chemotherapy.
  • After completion of local therapy, all patients received a sixth course of chemotherapy and a maintenance adjuvant chemotherapy regimen without anthracycline.
  • The median follow-up from the beginning of treatment was 140 months.
  • RESULTS: Mastectomy and axillary dissection were performed in 49 patients (with residual tumour larger than 3 cm in diameter or located behind the nipple or with bifocal tumour), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumour bed; 32 had residual mass <or=3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site).
  • After multivariate analysis, possibility of breast-conserving therapy was related to initial tumour size (<6 vs. >or=6 cm in diameter, p =0.002).
  • After multivariate analysis, metastatic disease-free survival rates were significantly influenced by clinical stage (stage IIIA-B vs. IIIC, p =0.0003), N-stage (N0 vs. N1-2a, and 3c, p =0.017), initial tumour size (<6 vs. >or=6 cm in diameter, p =0.008), and tumour response after induction chemotherapy and preoperative irradiation (clinically complete response + partial response vs. non-response, p =0.0015).
  • In the non conservative breast treatment group, of the 32 patients with no change in clinical tumour size after induction chemotherapy, the 10-year metastatic disease-free survival rate was 59% with only one local relapse.
  • On the other hand, the rate of local failure seems to be high in patients with clinical partial tumour response following induction chemotherapy and breast-conserving treatment combining preoperative irradiation and large wide excision.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Mastectomy. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217583.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Reefy S, Patani N, Anderson A, Burgoyne G, Osman H, Mokbel K: Oncological outcome and patient satisfaction with skin-sparing mastectomy and immediate breast reconstruction: a prospective observational study. BMC Cancer; 2010;10:171
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nipple reconstruction was performed in 69 patients, using the trefoil local flap technique (n = 61), nipple sharing (n = 6), skin graft (n = 1) and Monocryl mesh (n = 1).
  • Overall breast cancer specific survival was 99.2%, 8 patients developed distant disease and 1 died of metastatic BC.
  • Morbidities included infection, requiring implant removal in 2 patients and 1 patient developed marginal ischaemia of the skin envelope.
  • Chemotherapy was delayed in 1 patient due to infection.
  • [MeSH-minor] Adult. Aged. Breast Implantation. Chemotherapy, Adjuvant. Female. Humans. London. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nipples / surgery. Radiotherapy, Adjuvant. Skin / pathology. Skin Transplantation. Surgical Flaps. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):140-6 [17112698.001]
  • [Cites] Breast J. 2006 May-Jun;12(3):194-8 [16684314.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1220-5 [17579346.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33(10):1142-5 [17490847.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):143-8 [17709228.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):38-45; discussion 45 [18209151.001]
  • [Cites] Breast Cancer Res Treat. 2008 Oct;111(3):391-403 [17965954.001]
  • [Cites] Am Surg. 2008 Oct;74(10):902-5 [18942610.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3396-401 [18923874.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):461-8 [19247035.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):544-8 [10947024.001]
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):165-8 [11888874.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):814-9 [12035037.001]
  • [Cites] Ann Surg Oncol. 2002 Jun;9(5):462-6 [12052757.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):706-11 [12560691.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):95-7 [12620899.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):102-7 [12620902.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):108-12 [12620903.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):191-7 [12633565.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):120-7 [12832974.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):885-99 [12875600.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):995-1013 [12875606.001]
  • [Cites] Ann Plast Surg. 2003 Dec;51(6):547-51 [14646645.001]
  • [Cites] Ann Plast Surg. 2004 Jan;52(1):15-21 [14676693.001]
  • [Cites] Plast Reconstr Surg. 2004 Mar;113(3):877-81 [15108879.001]
  • [Cites] Plast Reconstr Surg. 2004 May;113(6):1617-28 [15114121.001]
  • [Cites] Am J Surg. 2004 Jul;188(1):78-84 [15219490.001]
  • [Cites] Plast Reconstr Surg. 1995 Oct;96(5):1111-5; discussion, 1116-8 [7568487.001]
  • [Cites] Ann Surg. 1997 May;225(5):570-5; discussion 575-8 [9193184.001]
  • [Cites] Eur J Surg Oncol. 1998 Feb;24(1):15-6 [9542508.001]
  • [Cites] Plast Reconstr Surg. 1998 Jul;102(1):49-62 [9655407.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):609-13 [10493632.001]
  • [Cites] Am J Surg. 2005 Dec;190(6):918-22 [16307946.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):438-43 [17826052.001]
  • (PMID = 20429922.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2873394
  •  go-up   go-down


7. Naguib SF: Oncoplastic resection of retroareolar breast cancer: central quadrantectomy and reconstruction by local skin-glandular flap. J Egypt Natl Canc Inst; 2006 Dec;18(4):334-47
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with central breast neoplasms account for 5 to 20% of breast cancer cases and, for a long time, they have been denied Breast Conservation Surgery (BCS) and conventionally treated with mastectomy.
  • The high incidence of Nipple-Areola-Complex (NAC) involvement usually associated with these tumors necessitates nipple and areolar resection together with an adequate safety margin around the tumor, which yields an unacceptable cosmetic result.
  • Twenty-two had a palpable mass, while only 1 had Paget's disease of the nipple without mass.
  • Only 9 women showed clinical suspicion of NAC involvement in the form of nipple retraction.
  • All patients underwent central quadrantectomy with NAC resection removing a cylinder of breast tissue reaching down to the pectoral muscle together with axillary dissection.
  • All patients received adjuvant radiotherapy with or without chemotherapy or hormonal therapy.
  • RESULTS: Fourteen patients showed pathological evidence of nipple infiltration (60.8%).
  • The procedure lasted a mean time of 195+/-12.7 minutes and blood loss was estimated at a mean of 225+/-64.8 mL.
  • The procedure did not delay the start of adjuvant treatment nor did it hamper clinical and mammographic follow-up.
  • Central quadrantectomy with repair by a skin-glandular flap is a relatively simple procedure that yields very satisfactory cosmetic results with minimal complications and it may be considered as one of the noteworthy therapeutic options for patients with central breast tumors.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Nipples / surgery. Postoperative Complications. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301457.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


8. Horii R, Akiyama F, Kasumi F, Koike M, Sakamoto G: Spontaneous " healing" of breast cancer. Breast Cancer; 2005;12(2):140-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Healing is a phenomenon by which the intraductal component of breast cancer disappears and is replaced by fibrous tissue.
  • PATIENTS AND METHODS: At our hospital, 308 patients (311 breasts) underwent breast conservation therapy without neoadjuvant chemotherapy for breast cancer in 2000.
  • (1) The proportion of breast cancer with healing was 7% (21/311). (2) In the 21 patients, the mean age was 59.2 years, and the mean diameter was 2.8 cm. (3) The histological type of the breast cancer varied: noninvasive ductal carcinoma in 2 cases, papillotubular carcinoma in 5, solid-tubular carcinoma in 8, scirrhous carcinoma in 5, invasive lobular carcinoma in 1, and Paget's disease in 1.
  • However in all cases, the histologic type of the intraductal carcinoma foci was the comedo/solid type and the nuclear grade of cancer cells was high. (4) In cases with healing, areas of healing were seen in an average of 5 (1-26) blocks, compared with intraductal carcinoma foci in 13 blocks (2-40).
  • Healing was located on the nipple side of the main lesion in 8 cases, the peripheral side in 9, and both sides in 4.
  • CONCLUSION: The proportion of breast cancer cases with healing was 7% and these cases were intraductal carcinoma of the comedo/solid type, consisting of highly malignant cancer cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / therapy. Carcinoma / therapy. Neoplasm Regression, Spontaneous / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858446.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


9. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J: Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys; 2004 Jul 15;59(4):1062-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
  • PURPOSE: To evaluate our updated data concerning survival and locoregional control in a prospective study of locally advanced noninflammatory breast cancer (LABC) after primary chemotherapy (CT) followed by external preoperative irradiation (RT).
  • METHODS AND MATERIALS: Between 1982 and 1998, 120 patients (75 Stage IIIA, 41 Stage IIIB, and 4 Stage IIIC according to AJCC staging system 2002) were treated by four courses of induction CT with anthracycline-containing combinations followed by preoperative RT (45 Gy to the breast and nodal areas) and a fifth course of CT.
  • Three different locoregional approaches were proposed depending on tumor characteristics and tumor response.
  • After completion of local therapy, all patients received a sixth course of CT and a maintenance adjuvant CT regimen without anthracycline.
  • The median follow-up from the beginning of treatment was 140 months.
  • RESULTS: Mastectomy and axillary dissection were performed in 49 patients (with residual tumor larger than 3 cm in diameter or located behind the nipple or with bifocal tumor), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumor bed; 32 had residual mass < or =3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site).
  • After multivariate analysis, possibility of breast-conserving therapy was related to initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.002).
  • After multivariate analysis, metastatic disease-free survival rates were significantly influenced by clinical stage (Stage IIIA-B vs. IIIC, p = 0.0003), N-stage (N0 vs. N1-2a, and 3c, p = 0.017), initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.008), and tumor response after induction CT and preoperative RT (clinically complete response + partial response vs. nonresponder, p = 0.0015).
  • In the nonconservative breast treatment group, of the 32 patients with no change in clinical tumor size after induction CT, the 10-year metastatic disease-free survival rate was 59% with only one local relapse.
  • On the other hand, the rate of local failure seems to be high in patients with clinical partial tumor response after induction CT and breast-conserving treatment combining preoperative RT and large wide excision.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cobalt Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234040.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


10. Hali F, Chiheb S, El Ouazzani T, Lakhdar H: [Male breast cancer in Morocco]. Ann Dermatol Venereol; 2002 May;129(5 Pt 1):699-702
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cancer du sein chez l'homme au Maroc.
  • The aim of this work was to analyze the different clinical and therapeutic features for this disease in men.
  • The skin was involved by tumor in 11 cases.
  • Ulceration of the skin by tumor was seen in eight patients, and direct extension of the tumor into the nipple without ulceration was seen in three patients.
  • Treatment was usually surgical.
  • Complementary treatment included radiotherapy, chemotherapy and/or hormonotherapy.
  • DISCUSSION: Although breast cancer in men is far less common than breast cancer in women, it is associated with less favorable prognosis because diagnosis is usually made at an advanced stage.
  • Concerted efforts must be made to educate both the public and health professionals, in order to make earlier diagnosis and thereby improve prognosis.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12124511.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Seetharam S, Fentiman IS: Paget's disease of the nipple. Womens Health (Lond); 2009 Jul;5(4):397-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paget's disease of the nipple.
  • Paget's disease of the nipple is an unusual epidermal presentation of underlying breast cancer.
  • Mastectomy maximizes local control; however, selected cases can be treated by nipple conisation with radiotherapy.
  • Almost all invasive cases overexpress human EGF receptor-2 and, therefore, are likely to benefit from adjuvant chemotherapy and herceptin.
  • [MeSH-major] Breast Neoplasms / diagnosis. Nipples / pathology. Paget's Disease, Mammary / diagnosis
  • [MeSH-minor] Axilla / pathology. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / diagnosis. Receptor, ErbB-2 / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586431.001).
  • [ISSN] 1745-5065
  • [Journal-full-title] Women's health (London, England)
  • [ISO-abbreviation] Womens Health (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 22
  •  go-up   go-down


12. Fan ZM, Song D, Wang L, Fu T, Yang M, Liu GJ: [Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer]. Zhonghua Yi Xue Za Zhi; 2007 Jan 9;87(2):93-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer].
  • OBJECTIVE: To study the feasibility of total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer.
  • METHODS: The 20 patients with breast cancer (TNM stage I, 6 patients; stage II, 14 patients) underwent the total mastectomy axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis.
  • Post-operation they were given chemotherapy, radiotherapy, endocrine therapy.
  • CONCLUSION: Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis on selected patients with breast cancer is an oncologically acceptable procedure with superior cosmetic results, without increasing the risk of local recurrences, complications and influencing the effects of postoperative adjuvant treatment.
  • [MeSH-minor] Adult. Feasibility Studies. Female. Follow-Up Studies. Humans. Neoplasm Staging. Nipples / surgery

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418014.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Ralleigh G, Walker AE, Hall-Craggs MA, Lakhani SR, Saunders C: MR imaging of the skin and nipple of the breast: differentiation between tumour recurrence and post-treatment change. Eur Radiol; 2001;11(9):1651-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of the skin and nipple of the breast: differentiation between tumour recurrence and post-treatment change.
  • We looked specifically at the appearances of the skin and nipple of the treated breast in order to describe the appearances of post-treatment change and recurrence in this region.
  • Thirty-nine women treated for breast cancer had MR imaging of one or both breasts reviewed retrospectively with particular attention to the nipple and skin.
  • All available histology of the skin and/or nipple, obtained following MR imaging, was reviewed.
  • Six of 39 cases had nodular enhancing areas seen on MR imaging, which correlated with histology demonstrating tumour recurrence within the skin and/or nipple.
  • Of the remaining 33 patients, changes of linear or diffuse enhancement were seen in the skin and/or nipple of 15 patients.
  • These changes were shown to be benign post-treatment changes at surgery/biopsy in 4 cases or by clinical follow-up in the remainder.
  • In this article we demonstrate differing patterns of contrast enhancement within the skin and nipple in recurrent breast carcinoma vs. post-treatment changes.
  • This suggests that contrast-enhanced MR imaging of the breast may be a useful tool in differentiating tumour recurrence from post-treatment changes within the skin and nipple.
  • [MeSH-major] Breast Neoplasms / diagnosis. Image Enhancement. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis. Nipples. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiotherapy. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Breast / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / radiotherapy. Carcinoma, Lobular / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Mastectomy. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Retrospective Studies. Sensitivity and Specificity. Skin / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11511886.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Köbrunner SH, Kaiser WA, Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer H, Orecchia R, Panizza P, Ponti A, Purushotham AD, Regitnig P, Del Turco MR, Thibault F, Wilson R: Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer; 2010 May;46(8):1296-316
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the following ten indications, an overview of the evidence, a list of recommendations, and a number of research issues were defined: staging before treatment planning; screening of high-risk women; evaluation of response to neoadjuvant chemotherapy; patients with breast augmentation or reconstruction; occult primary breast cancer; breast cancer recurrence; nipple discharge; characterisation of equivocal findings at conventional imaging; inflammatory breast cancer; and male breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Evidence-Based Medicine. Female. Humans. Italy. Male. Mammaplasty. Neoplasm Recurrence, Local / diagnosis. Patient Selection

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20304629.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] England
  • [Number-of-references] 223
  •  go-up   go-down


15. Madej B, Balak B, Winkler I, Burdan F: Cancer of the accessory breast--a case report. Adv Med Sci; 2009;54(2):308-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast neoplasm may develop in ectopically located glandular tissue.
  • This paper presents an interesting and rare case of a 50-year-old female who despite regular mammography screening examination developed an invasive accessory breast cancer.
  • The lesion was immobile, the skin and the atrophic nipple were retracted, the tumour infiltrated the thoracic wall.
  • The patient was submitted to pre-operative chemotherapy.
  • She also underwent surgery and subsequently post-operative chemotherapy and radiotherapy.
  • Preventive resection of accessory breast in women at high risk of developing breast cancer can be considered as the treatment of choice in most patients.
  • [MeSH-minor] Biopsy. Female. Humans. Mammary Glands, Human / pathology. Middle Aged. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Staging. Nipples / pathology. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis


16. Caliskan M, Gatti G, Sosnovskikh I, Rotmensz N, Botteri E, Musmeci S, Rosali dos Santos G, Viale G, Luini A: Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat; 2008 Dec;112(3):513-21
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Paget's disease of the breast is an uncommon presentation of breast malignancy, accounting for 1-3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia.
  • In the literature, different methods are used for the treatment.
  • Mastectomy with or without axillary dissection has been considered as the standard treatment procedure for many years.
  • Several studies have already shown that breast conservation with radiation therapy is an oncologically safe option.
  • The median age of the patients was 54 years at the time of the diagnosis.
  • Each patient was evaluated after surgery at a multidisciplinary meeting to selecting systemic therapy.
  • Adjuvant systemic therapies were based on the final tumor, node and metastasis stage: thirty patients received adjuvant chemotherapy alone, fourteen received endocrine treatment alone, twenty-six patients were evaluated to receive both chemo and endocrine therapy.
  • Five patients developed local recurrence, one had regional recurrence, another two had loco-regional recurrences and fourteen had distant metastasis as a first event.
  • Malignancy-related deaths were censored in the statistical analyses cancer for and due to another tumor in eleven patients.
  • Breast conserving surgery combined with breast irradiation for patients with invasive and non invasive breast carcinoma has become the treatment of first choice.
  • All surgical conservative approaches should include the complete nipple-areolar complex and margins of resected specimen free of tumor.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Paget's Disease, Mammary / diagnosis. Paget's Disease, Mammary / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / pathology. Clinical Trials as Topic. Female. Humans. Mastectomy. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sentinel Lymph Node Biopsy / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240020.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Mannell A: Breast-conserving therapy in breast cancer patients--a 12-year experience. S Afr J Surg; 2005 May;43(2):28-30; discussion 30, 32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast-conserving therapy in breast cancer patients--a 12-year experience.
  • INTRODUCTION: Twenty years ago prospective randomised controlled trials were initiated to compare conservative breast surgery plus radiation with radical mastectomy in the treatment of early-stage breast cancer.
  • The results have shown no survival advantage for mastectomy over breast-conserving therapy (BCT).
  • Adjuvant therapy (hormones, chemotherapy) was undertaken, and the incidence and times of local recurrence and distant metastases were recorded.
  • At a median follow-up of 65 months one patient developed local recurrence (LR) in the breast synchronously with distant relapse.
  • The segment containing the cancer should be resected from the nipple to the periphery of the breast.
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035379.001).
  • [ISSN] 0038-2361
  • [Journal-full-title] South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie
  • [ISO-abbreviation] S Afr J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


18. Bakheet SM, Bakheet R, Ezzat A, Tulbah A, Durakovic A, Hussain S: F-18 FDG positron emission tomography in primary breast non-Hodgkin's lymphoma. Clin Nucl Med; 2001 Apr;26(4):299-301
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG positron emission tomography in primary breast non-Hodgkin's lymphoma.
  • A 50-year-old woman had an irregular, mobile, firm right breast mass that became progressively larger in the past 3 months that measured 18 x 15 cm at the time of examination.
  • She had no nipple discharge or skin changes.
  • A 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) showed a ring-shaped breast uptake consisting of high peripheral glycolytic activity and a cold center most likely representing necrosis or hemorrhage despite the absence of a history of trauma, surgical intervention, chemotherapy, or radiation to the breast.
  • These results were confirmed by computed tomography of the chest, abdomen, and pelvis.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11290887.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Katz A, Strom EA, Buchholz TA, Theriault R, Singletary SE, McNeese MD: The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys; 2001 Jul 1;50(3):735-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy.
  • PURPOSE: The objective of this study was to evaluate the influence of pathologic factors other than tumor size and number of involved axillary nodes on the risk of locoregional recurrence (LRR) following mastectomy.
  • PATIENTS AND METHODS: We reviewed the medical records of 1031 patients treated with mastectomy and doxorubicin-based chemotherapy without radiation on 5 prospective clinical trials.
  • Patients with lymph-vascular space invasion (LVSI) or involvement of the skin or nipple also experienced high rates of LRR (25%, 32%, and 50%, respectively).
  • On multivariate analysis, the presence of 4 or more involved axillary nodes, tumor size of greater than 5 cm, close or positive surgical margins, and gross multicentric disease were found to be independent predictors of LRR (all, p < 0.01).
  • In a separate analysis including only patients with 1-3 involved axillary nodes, microscopic invasion of the skin or nipple, pectoral fascial invasion, and the presence of close or positive margins were significant predictors of LRR.
  • CONCLUSION: In addition to the extent of primary and nodal disease, other factors that predict for high rates of LRR include the presence of LVSI, involvement of the skin, nipple or pectoral fascia, close or positive margins, or gross multicentric disease.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395242.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Gherardini G, Thomas R, Basoccu G, Zaccheddu R, Fortunato L, Cortino P, Evans GR, Matarasso A, D'Aiuto M, D'Aiuto G: Immediate breast reconstruction with the transverse rectus abdominis musculocutaneous flap after skin-sparing mastectomy. Int Surg; 2001 Oct-Dec;86(4):246-51
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immediate breast reconstruction with the transverse rectus abdominis musculocutaneous (TRAM) flap after skin-sparing mastectomy is becoming an increasingly performed procedure in patients with ductal carcinoma in situ, early invasive breast cancer, and prophylactic mastectomy.
  • Through a periareolar approach, it is possible to remove the breast parenchyma along with the nipple areola complex, preserving almost all the original skin envelope and the inframmamary fold.
  • The major disadvantages, extensive scar and donor site skin color mismatch, are reduced to a minimum level because the former is limited at the natural border of the nipple areola and the latter can be effectively concealed with proper nipple reconstruction.
  • Requirements for the skin-sparing mastectomy technique include suitability of donor site tissue for autologous tissue, early breast cancer or ductal carcinoma in situ, and adequate size and shape matching of the contralateral breast.
  • One patient developed abdominal bulging 1 month after the operation, during the administration of chemotherapy.
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Rectus Abdominis / surgery. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056470.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Ballester M, Berry M, Couturaud B, Reyal F, Salmon RJ, Fitoussi AD: Lateral mammaplasty reconstruction after surgery for breast cancer. Br J Surg; 2009 Oct;96(10):1141-6
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Up to 60 per cent of cancers develop laterally in the breast and breast-conserving surgery frequently produces superolateral nipple-areolar complex (NAC) distortion aggravated by postoperative irradiation.
  • It is an option when a deformity is anticipated after breast-conserving surgery, and is particularly valuable when neoadjuvant chemotherapy has downgraded a large tumour.
  • [MeSH-minor] Adult. Aged. Calcinosis / surgery. Esthetics. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / surgery. Patient Satisfaction. Postoperative Complications / surgery. Reoperation. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787762.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Iizuka M, Sengoku N, Nakakuma T, Yoshimura N, Hayashi K, Enomoto T, Kuranami M, Watanabe M: [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2228-30
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
  • We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL.
  • A 40-year-old woman visited our hospital because of her left breast tumor.
  • On physical examination, the tumor had invaded to the skin adjacent to the nipple forming a skin ulcer and marked deformity of the entire breast.
  • Subsequently, radiographic imaging tests revealed that the tumor had metastasized to the liver and lungs, as well as the skull.
  • Accordingly, a primary systemic chemotherapy (4 series of AC/T) was started and followed by local radiation therapy (60 Gys) immediately after completing the chemotherapy.
  • The metastasizing lesions in the liver, lungs, and skull had markedly reduced in the size and number, and the skin ulceration had healed up by these treatments.
  • She has been quite well without any adverse effects by S-1 and TAM, and the primary as well as metastasizing lesions remain stable with normalized tumor marker levels (NC) for nearly 3 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Drug Combinations. Female. Humans. Mitoxantrone / therapeutic use. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed. Topotecan / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106579.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 04079A1RDZ / Cytarabine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; AC protocol; TAM protocol
  •  go-up   go-down


23. Petrocca S, La Torre M, Cosenza G, Bocchetti T, Cavallini M, Di Stefano D, Sammartino F, Ziparo V: Male breast cancer: a case report and review of the literature. Chir Ital; 2005 May-Jun;57(3):365-71
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of its rarity little is known about its aetiology, clinical behaviour and treatment.
  • Nevertheless, because of the absence of screening protocols and the limited amount of mammary tissue in men, allowing rapid local infiltration, a late diagnosis is often made, with a poor survival rate.
  • Most of our current knowledge about the biology, natural history, surgical therapeutic strategies, adjuvant radiotherapy and chemotherapy protocols of male breast carcinoma has been extrapolated from its female counterpart.
  • The Authors report the case of a male patient with breast cancer and pagetoid diffusion in the nipple region, and, on the basis of a review of the literature, summarise what is currently known about this rare neoplasm in terms of prognostic factors, therapy and survival.
  • [MeSH-minor] Aged. Humans. Male. Mastectomy, Radical / methods. Neoadjuvant Therapy / methods. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231827.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 39
  •  go-up   go-down


24. Kronowitz SJ, Hunt KK, Kuerer HM, Strom EA, Buchholz TA, Ensor JE, Koutz CA, Robb GL: Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg; 2007 Dec;120(7):1755-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy.
  • BACKGROUND: The authors previously compared the local tissue rearrangement, breast reduction, and latissimus dorsi flap reconstruction techniques for repairing partial mastectomy defects and showed the benefits of breast reduction.
  • RESULTS: Tumor location had a significant effect on the design of the parenchymal pedicle (p = 0.05).
  • Fifty percent of the lower outer and central quadrant tumors required an amputative design with a free nipple graft.
  • Ninety percent of patients with planned repairs had a viable nipple-areola complex (p = 0.05) and did not require a free nipple graft.
  • Only 7 percent of patients had a positive tumor margin.
  • Five percent of patients developed local breast cancer recurrence after a mean follow-up of 36 months.
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Esthetics. Fat Necrosis / epidemiology. Fat Necrosis / etiology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Nipples / surgery. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Practice Guidelines as Topic. Retrospective Studies. Seroma / epidemiology. Seroma / etiology. Surgical Flaps. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2008 Aug;122(2):675-6; author reply 676-7 [18626402.001]
  • (PMID = 18090737.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Matsui K, Tazawa K, Karato M, Nagata T, Shimada Y, Tsukada K: [An elderly advanced breast cancer with a good response to anastrozole]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1557-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In December 2005, she became aware of a tumor in her right breast at the nipple, gradually increasing in size and bleeding, and visited our department in April 2006.
  • Roughly 3.5 cm in size, the tumor had a prominent large skin surface, bled profusely, and a dark red-colored was found at the E area of the right breast.
  • Ultrasonography and mammography revealed that the tumor had invaded the skin and pectoralis major muscle (T4b).
  • We started anastrozole 1mg/day treatment.
  • Tumor blood loss after one month was confirmed.
  • After six months, the primary tumor size was reduced to 2 cm and the axillary lymph nodes disappeared.
  • Administration continued about three years, and the tumor showed only the scar-like changes, and was unclear from ultrasonography (cPR).
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Breast Neoplasms / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716886.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


26. Sauter ER, Ganz PA, Ehya H, Hewett JE, Schlatter L, Kliethermes B, Daly MB: Prospective multicenter trial to determine the feasibility of collection and predictive ability of breast fluid analysis in postmenopausal women receiving SERMs. Breast; 2007 Oct;16(5):489-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) our ability to collect nipple aspirate fluid (NAF) in postmenopausal women taking medication to decrease breast proliferation and (2) NAF biomarkers associated with breast cancer.
  • NAF was collected before and 6 months after starting treatment.
  • We were able to collect fluid in 84% of the subjects who produced NAF at baseline and returned for second aspiration after 6 months of treatment.
  • Median PSA increased from 37.5 to 112 ng/L after treatment.
  • In conclusion, after treatment with tamoxifen or raloxifene, changes in both NAF cytology and PSA were generally favorable, consistent with their expected antiproliferative effective effect on the breast.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Body Fluids / chemistry. Breast Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nipples / pathology. Selective Estrogen Receptor Modulators / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Postmenopause. Predictive Value of Tests. Prospective Studies. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482465.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Selective Estrogen Receptor Modulators
  •  go-up   go-down






Advertisement